Autolus Therapeutics (AUTL) director reports existing stock option grants

Rhea-AI Filing Summary

Autolus Therapeutics plc director Michael W. Bonney has filed an initial Form 3 showing his beneficial ownership of stock options over American Depositary Shares. The filing lists three option positions: one over 120,000 ADSs with a $5.6800 exercise price expiring on April 1, 2034, and two over 80,000 ADSs each with exercise prices of $3.4800 and $2.3200, expiring on June 28, 2034 and June 26, 2035 respectively. Footnotes explain that one grant vests in 36 equal monthly installments from May 1, 2024, one is already fully vested and exercisable, and another vests in twelve equal monthly installments from July 26, 2025. This Form 3 is a disclosure of existing derivative holdings rather than a report of new market purchases or sales.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider BONNEY MICHAEL W

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 120,000 shares (Direct)

Footnotes (1)

1. This option vested or vests in 36 equal monthly installments commencing on May 1, 2024. Fully vested and exercisable. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BONNEY MICHAEL W

(Last) (First) (Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	04/01/2034	American Depositary Shares	120,000	$5.68	D
Share Option (right to buy)	(2)	06/28/2034	American Depositary Shares	80,000	$3.48	D
Share Option (right to buy)	(3)	06/26/2035	American Depositary Shares	80,000	$2.32	D

Explanation of Responses:

1. This option vested or vests in 36 equal monthly installments commencing on May 1, 2024.

2. Fully vested and exercisable.

3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

	/s/ Michael Bonney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Michael W. Bonney’s Form 3 for Autolus Therapeutics (AUTL) show?

The Form 3 shows Michael W. Bonney’s existing stock option holdings in Autolus Therapeutics. It lists three option grants over American Depositary Shares with specified exercise prices, expiration dates, and vesting schedules, but does not report any new open‑market purchases or sales.

How many Autolus Therapeutics ADSs are covered by Michael Bonney’s options on this Form 3?

The Form 3 discloses three separate stock option positions over Autolus ADSs. One option covers 120,000 underlying ADSs, and two additional options each cover 80,000 underlying ADSs, all held directly as reported derivative positions by director Michael W. Bonney.

What are the exercise prices and expirations of Michael Bonney’s Autolus (AUTL) options?

Bonney’s options have exercise prices of $5.6800, $3.4800, and $2.3200. Their respective expiration dates are April 1, 2034, June 28, 2034, and June 26, 2035, according to the derivative holdings listed in the Form 3.

How do Michael Bonney’s Autolus options vest according to the Form 3 footnotes?

The footnotes describe three different vesting patterns for Bonney’s options. One option vests in 36 equal monthly installments from May 1, 2024, another is fully vested and exercisable, and a third vests in twelve equal monthly installments beginning July 26, 2025.

Does Michael W. Bonney buy or sell Autolus Therapeutics shares in this Form 3 filing?

No, this Form 3 does not report any purchases or sales of Autolus shares. It is an initial beneficial ownership statement listing existing stock option holdings, without open‑market buy or sell transactions or changes in net share ownership.